Press releases


August 2012

Press Release N° 1

Bogotá, Colombia, 26 August 2012

When faced with the lack of availability of the transmission line Tunal- San Mateo, Tunal- Circo, south of Bogotá, recorded by the Control Center, on 25 August, Empresa de Energía de Bogotá, EEB, immediately activated all its emergency service protocols, which include the report to pertinent authorities and the valuation of damages, where they were able to establish that the root cause of the event was due to the cut of structural elements in the main tower. Once the damage was fixed and valued, the necessary actions were taken to repair the tower, which includes a team of more than 25 specialized workers and all technical provisions required to re-establish service as fast as possible in said infrastructure.The event did not affect the rendering of electric service in the city of Bogota.

About Grupo Energía de Bogotá
Grupo Energía de Bogotá is a leading corporation in the Colombian energy sector.  Through EEB it transports electricity to the largest and most significant markets in the country, in addition to exercising control over the largest natural gas transporter in Colombia, TGI S.A.  In Perú, its company CONTUGAS has a 30 year concession to transport and distribute natural gas in the Ica Department, while  Calidda distributes natural gas in Lima and Callao.  In the same country, together with ISA, it participates in REP S.A. and TRANSMANTARO S.A. that operate 63% of the electricity transmission system in that country. In 2010 it incorporated TRECSA - Transportadora de Centroamérica S.A.- , a company which will build the largest and most important infrastructure power project in Guatemala and will render electricity transmission services as of Q 2013.  Furthermore, it has a portfolio of investments in significant companies in the power sector, amongst which one may highlight CODENSA S.A., EMGESA S.A., GAS NATURAL S.A., la Empresa de Energía de Cundinamarca - EEC and  Electrificadora del Meta, EMSA and to a lesser extent ISA and ISAGEN.